Healthcare provider profile · identity verified

April Laverne Buscher, MD, MPH

Family Practice · DURHAM, NC · NPI 1609097708

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	342	64
Amlodipine Besylate	Amlodipine Besylate	307	49
Omeprazole	Omeprazole	182	26
Albuterol Sulfate Hfa	Albuterol Sulfate	160	29
Gabapentin	Gabapentin	123	19
Fluticasone Propionate	Fluticasone Propionate	122	24
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	111	13
Tivicay	Dolutegravir Sodium	111	suppressed
Lisinopril	Lisinopril	107	17
Metformin Hcl	Metformin Hcl	106	19
Tamsulosin Hcl	Tamsulosin Hcl	106	22
Carvedilol	Carvedilol	103	16
Losartan Potassium	Losartan Potassium	102	21
Potassium Chloride	Potassium Chloride	102	16
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	98	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	86	suppressed
Spironolactone	Spironolactone	82	13
Ventolin Hfa	Albuterol Sulfate	77	14
Allopurinol	Allopurinol	71	suppressed
Duloxetine Hcl	Duloxetine Hcl	71	14
Metoprolol Succinate	Metoprolol Succinate	71	16
Jardiance	Empagliflozin	70	13
Hydrochlorothiazide	Hydrochlorothiazide	60	15
Furosemide	Furosemide	59	15
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	59	suppressed
Alendronate Sodium	Alendronate Sodium	55	suppressed
Mounjaro	Tirzepatide	55	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	52	suppressed
Telmisartan-Amlodipine	Telmisartan/Amlodipine	52	suppressed
Atenolol	Atenolol	51	suppressed
Finasteride	Finasteride	47	suppressed
Ozempic	Semaglutide	47	suppressed
Pregabalin	Pregabalin	46	suppressed
Montelukast Sodium	Montelukast Sodium	45	suppressed
Ezetimibe	Ezetimibe	44	suppressed
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	44	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	44	suppressed
Baclofen	Baclofen	43	suppressed
Metformin Hcl Er	Metformin Hcl	43	suppressed
Clopidogrel	Clopidogrel Bisulfate	42	suppressed
Ibuprofen	Ibuprofen	42	suppressed
Pravastatin Sodium	Pravastatin Sodium	41	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	40	suppressed
Oxycodone Hcl	Oxycodone Hcl	38	suppressed
Meloxicam	Meloxicam	36	suppressed
Chlorthalidone	Chlorthalidone	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Naproxen	Naproxen	33	suppressed
Levetiracetam	Levetiracetam	32	suppressed
Prednisone	Prednisone	31	suppressed
Spiriva Handihaler	Tiotropium Bromide	31	suppressed
Glipizide Er	Glipizide	30	suppressed
Sertraline Hcl	Sertraline Hcl	30	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	29	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	11
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Januvia	Sitagliptin Phosphate	28	suppressed
Famotidine	Famotidine	25	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Telmisartan	Telmisartan	24	suppressed
Topiramate	Topiramate	24	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	23	suppressed
Eliquis	Apixaban	23	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Simvastatin	Simvastatin	21	suppressed
Abacavir	Abacavir Sulfate	20	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Lamivudine Hbv	Lamivudine	19	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Methocarbamol	Methocarbamol	18	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Hydrocortisone	Hydrocortisone	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Linzess	Linaclotide	16	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Ciclopirox	Ciclopirox	15	suppressed
Clotrimazole	Clotrimazole	15	suppressed
Darunavir	Darunavir	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Latanoprost	Latanoprost	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Desonide	Desonide	14	suppressed
Dovato	Dolutegravir Sodium/Lamivudine	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Isentress	Raltegravir Potassium	14	suppressed
Lactulose	Lactulose	14	suppressed
Lamivudine-Zidovudine	Lamivudine/Zidovudine	14	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	14	suppressed
Ritonavir	Ritonavir	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Trazodone Hcl	Trazodone Hcl	14	suppressed
Belbuca	Buprenorphine Hcl	13	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Pifeltro	Doravirine	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Symtuza	Darunavir/Cob/Emtri/Tenof Alaf	13	suppressed
Tramadol Hcl	Tramadol Hcl	13	suppressed
Glipizide	Glipizide	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Lamivudine	Lamivudine	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Triumeq	Abacavir/Dolutegravir/Lamivudi	12	suppressed
Zidovudine	Zidovudine	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Estradiol Valerate	Estradiol Valerate	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Juluca	Dolutegravir/Rilpivirine	11	suppressed
Methadone Hcl	Methadone Hcl	11	suppressed
Tretinoin	Tretinoin	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error